Overview

Safety and Tolerability of Oral CM082 in Patients With wAMD

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Intermittent Oral Dosing of CM082 tablets in Chinese Patients With wAMD.
Phase:
Phase 2
Details
Lead Sponsor:
AnewPharma
Collaborator:
Renmin Hospital of Wuhan University
Treatments:
Vorolanib